Compare FATE & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FATE | SCM |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.0M | 211.0M |
| IPO Year | 2013 | 2012 |
| Metric | FATE | SCM |
|---|---|---|
| Price | $2.07 | $7.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 5 |
| Target Price | $5.74 | ★ $10.13 |
| AVG Volume (30 Days) | ★ 1.1M | 120.6K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | ★ 14.04% |
| EPS Growth | ★ 29.88 | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $6,646,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.85 |
| P/E Ratio | ★ N/A | $11.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $6.54 |
| 52 Week High | $3.23 | $13.55 |
| Indicator | FATE | SCM |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 48.28 |
| Support Level | $1.78 | $6.83 |
| Resistance Level | $2.15 | $8.92 |
| Average True Range (ATR) | 0.13 | 0.18 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 60.42 | 77.33 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.